GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » COGS-to-Revenue

Centogene NV (Centogene NV) COGS-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV COGS-to-Revenue?

Centogene NV's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.00 Mil.

Centogene NV's COGS to Revenue for the three months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Centogene NV's Gross Margin % for the three months ended in Jun. 2023 was N/A%.


Centogene NV COGS-to-Revenue Historical Data

The historical data trend for Centogene NV's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV COGS-to-Revenue Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial 0.49 0.53 0.92 0.68 0.58

Centogene NV Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.62 0.59 - -

Centogene NV COGS-to-Revenue Calculation

Centogene NV's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=29.356 / 50.289
=0.58

Centogene NV's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centogene NV  (NAS:CNTG) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Centogene NV's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Centogene NV COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Centogene NV's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Centogene NV (Centogene NV) Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.